Bridging gaps in clinical trial accessibility and reimbursement for large B‐cell lymphoma therapies across Europe
Open Access
- 23 September 2025
- journal article
- Published by Wiley in HemaSphere
- Vol. 9 (9) , e70204
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Large B‐cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐upHemaSphere, 2025
- Using patient-reported outcomes and health-related quality of life data in regulatory decisions on cancer treatment: highlights from an EMA-EORTC workshopThe Lancet Oncology, 2025
- Technology Assessment vs. Technology Appraisal—How to Strengthen the Science/Value Dichotomy with EU HTA?Journal of Market Access & Health Policy, 2024
- EU HTA Regulation and Joint Clinical Assessment—Threat or Opportunity?Journal of Market Access & Health Policy, 2024
- Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell LymphomaNew England Journal of Medicine, 2022
- Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2015